Suppr超能文献

出生后24小时内预防性使用吲哚美辛,以预防在产房接受表面活性剂预防性治疗的早产儿动脉导管未闭。

Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room.

作者信息

Couser R J, Ferrara T B, Wright G B, Cabalka A K, Schilling C G, Hoekstra R E, Payne N R

机构信息

Division of Neonatology, Children's Health Care--Minneapolis, Minnesota 55404, USA.

出版信息

J Pediatr. 1996 May;128(5 Pt 1):631-7. doi: 10.1016/s0022-3476(96)80127-2.

Abstract

OBJECTIVE

To determine whether a course of low-dose indomethacin therapy, when initiated within 24 hours of birth, would decrease ductal shunting in premature infants who received prophylactic surfactant in the delivery room.

DESIGN

Ninety infants, with birth weights of 600 to 1250 gm, were entered into a prospective, randomized, controlled trial to receive either indomethacin, 0.1 mg/kg per dose, or placebo less than 24 hours and again every 24 hours for six doses. Echocardiography was performed on day 1 before treatment and on day 7, 24 hours after treatment. A hemodynamically significant patent ductus arteriosus (PDA) was confirmed with an out-of-study echocardiogram, and the nonresponders were treated with standard indomethacin or ligation.

RESULTS

Forty-three infants received indomethacin (birth weight, 915 +/- 209 gm; gestational age, 26.4 +/- 1.6 weeks; 25 boys), and 47 received placebo (birth weight, 879 +/- 202 gm; gestational age, 26.4 +/- 1.8 weeks; 22 boys) (P = not significant). Of 90 infants, 77 (86%) had a PDA by echocardiogram on the first day of life before study treatment; 84% of these PDAs were moderate or large in size in the indomethacin-treated group compared with 93% in the placebo group. Nine of forty indomethacin-treated infants (21%) were study-dose nonresponders compared with 22 (47%) of 47 placebo-treated infants (p < 0.018). There were no significant differences between both groups in any of the long-term outcome variables, including intraventricular hemorrhage, duration of oxygen therapy, endotracheal intubation, duration of stay in neonatal intensive care unit, time to regain birth weight or reach full caloric intake, incidence of bronchopulmonary dysplasia, and survival. No significant differences were noted in the incidence of oliguria, elevated plasma creatinine concentration, thrombocytopenia, pulmonary hemorrhage, or necrotizing enterocolitis.

CONCLUSION

The prophylactic use of low doses of indomethacin, when initiated in the first 24 hours of life in low birth weight infants who receive prophylactic surfactant in the delivery room, decreases the incidence of left-to-right shunting at the level of the ductus arteriosus.

摘要

目的

确定在出生后24小时内开始的低剂量吲哚美辛治疗疗程,是否会减少在产房接受预防性表面活性剂治疗的早产儿的动脉导管分流。

设计

90名出生体重在600至1250克之间的婴儿进入一项前瞻性、随机、对照试验,接受每剂0.1毫克/千克的吲哚美辛或安慰剂治疗,治疗时间少于24小时,之后每24小时给药一次,共给药六次。在治疗前第1天和治疗后第7天(治疗后24小时)进行超声心动图检查。通过研究外超声心动图确认存在血流动力学显著意义的动脉导管未闭(PDA),对无反应者采用标准吲哚美辛治疗或结扎治疗。

结果

43名婴儿接受吲哚美辛治疗(出生体重915±209克;胎龄26.4±1.6周;男婴25名),47名婴儿接受安慰剂治疗(出生体重879±202克;胎龄26.4±1.8周;男婴22名)(P值无显著差异)。90名婴儿中,77名(86%)在研究治疗前出生第一天的超声心动图检查显示有PDA;在吲哚美辛治疗组中,这些PDA中有84%为中度或大型,而安慰剂组为93%。40名接受吲哚美辛治疗的婴儿中有9名(21%)对研究剂量无反应,而47名接受安慰剂治疗的婴儿中有22名(47%)无反应(p<0.018)。两组在任何长期结局变量方面均无显著差异,包括脑室内出血、氧疗持续时间、气管插管、新生儿重症监护病房住院时间、恢复出生体重或达到全热量摄入的时间、支气管肺发育不良的发生率和生存率。在少尿发生率、血浆肌酐浓度升高、血小板减少、肺出血或坏死性小肠结肠炎方面未发现显著差异。

结论

对于在产房接受预防性表面活性剂治疗的低出生体重婴儿,在出生后24小时内开始预防性使用低剂量吲哚美辛,可降低动脉导管水平左向右分流的发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验